Transgenomic, Inc. a global biotechnology company
advancing precision medicine through advanced diagnostic tests and
clinical and research services, today announced that it is planning to
launch up to six new genetic cancer tests this year based on its
Multiplexed ICE COLD-PCR™ (MX-ICP) technology. The new tests will focus
on actionable genetic mutations and alterations in patients with
melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer, and
will include both single tests and multi-gene panels. Transgenomic’s
MX-ICP technology has demonstrated exceptional sensitivity and accuracy
using either standard tissue or liquid biopsy samples such as blood and
plasma. The tests are expected to be available for diagnostic use
through Transgenomic’s CLIA-certified laboratory.
"We are ahead of schedule in commercializing our pipeline of
laboratory-based cancer tests to meet the growing demand for targeted
and personalized cancer treatments," said Paul Kinnon, President and
Chief Executive Officer of Transgenomic. "The unsurpassed accuracy of
our Multiplexed ICE COLD-PCR technology and its ability to produce
highly sensitive and accurate results from small amounts of virtually
any type of patient sample enable its broad use for tumor detection and
monitoring."
No comments:
Post a Comment